Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia.

Autor: Mattiuzzi, Gloria N., Cortes, Jorge E., Blamble, Deborah A., Bekele, B. Nebiyou, Lianchun Xiao, Cabanillas, Maria, Borthakur, Gautam, O'Brien, Susan, Kantarjian, Hagop
Předmět:
Zdroj: Cancer (0008543X); 12/15/2010, Vol. 116 Issue 24, p5659-5666, 8p, 3 Charts, 3 Graphs
Abstrakt: This article discusses a study which compared two schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia (AML) receiving cytarabine. The study included 47 patients on ondansetron and 48 patients on each of the palonosetron. It revealed that the daily assessments of emesis did not show significant differences between the study arms.
Databáze: Complementary Index